CY1106259T1 - Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο - Google Patents

Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο

Info

Publication number
CY1106259T1
CY1106259T1 CY20061101619T CY061101619T CY1106259T1 CY 1106259 T1 CY1106259 T1 CY 1106259T1 CY 20061101619 T CY20061101619 T CY 20061101619T CY 061101619 T CY061101619 T CY 061101619T CY 1106259 T1 CY1106259 T1 CY 1106259T1
Authority
CY
Cyprus
Prior art keywords
taxane
class
warm
human
producing
Prior art date
Application number
CY20061101619T
Other languages
English (en)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1106259T1 publication Critical patent/CY1106259T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μία μέθοδο για την παραγωγή ενός αντιαγγειογόνου αποτελέσματος και/ή τη μείωση της αγγειακής διαπερατότητας σ' ένα θερμόαιμο ζώο όπως ο άνθρωπος, ιδιαίτερα σε μία μέθοδο για την αντιμετώπιση ενός καρκίνου που συμπεριλαμβάνει ένα συμπαγή όγκο, η οποία περιλαμβάνει τη χορήγηση ZD6474 σε συνδυασμό μ' ένα ταξάνιο• σε μία φαρμακευτική σύνθεση που περιέχει ZD6474 κι ένα ταξάνιο• σ' ένα συνδυασμένο προϊόν που περιέχει ZD6474 κι ένα ταξάνιο για χρήση σε μία μέθοδο θεραπευτικής αγωγής σε σώμα ανθρώπου ή ζώου• σ' ένα κιτ που περιλαμβάνει ZD6474 κι ένα ταξάνιο˙ στη χρήση του ZD6474 κι ενός ταξανίου στην παρασκευή ενός φαρμάκου για χρήση στην παραγωγή ενός αντιαγγειογόνου αποτελέσματος και/ή τη μείωση της αγγειακής διαπερατότητας σ' ένα θερμόαιμο ζώο όπως ο άνθρωπος που προαιρετικά μπορεί να υποβάλλεται σε ιονίζουσα ακτινοβολία.
CY20061101619T 2001-11-08 2006-11-09 Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο CY1106259T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0126879.6A GB0126879D0 (en) 2001-11-08 2001-11-08 Combination therapy
PCT/GB2002/005021 WO2003039551A1 (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane

Publications (1)

Publication Number Publication Date
CY1106259T1 true CY1106259T1 (el) 2011-06-08

Family

ID=9925430

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101619T CY1106259T1 (el) 2001-11-08 2006-11-09 Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο

Country Status (23)

Country Link
US (2) US20050043395A1 (el)
EP (1) EP1446124B1 (el)
JP (1) JP4694127B2 (el)
KR (1) KR100959607B1 (el)
CN (1) CN1298328C (el)
AR (1) AR037346A1 (el)
AT (1) ATE335488T1 (el)
AU (1) AU2002337382B2 (el)
BR (1) BR0213906A (el)
CA (1) CA2464758C (el)
CY (1) CY1106259T1 (el)
DE (1) DE60213845T2 (el)
DK (1) DK1446124T3 (el)
ES (1) ES2269769T3 (el)
GB (1) GB0126879D0 (el)
HK (1) HK1068546A1 (el)
IL (2) IL161744A0 (el)
MX (1) MXPA04004355A (el)
NO (1) NO328048B1 (el)
NZ (1) NZ532525A (el)
PT (1) PT1446124E (el)
WO (1) WO2003039551A1 (el)
ZA (1) ZA200403455B (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100376567C (zh) 1999-11-05 2008-03-26 阿斯特拉曾尼卡有限公司 作为vegf抑制剂的喹唑啉衍生物
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
DE60121931T2 (de) * 2000-04-07 2007-03-01 Astrazeneca Ab Chinazolinverbindungen
KR101093345B1 (ko) 2002-02-01 2011-12-14 아스트라제네카 아베 퀴나졸린 화합물
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
DK1592423T3 (da) * 2003-02-13 2011-06-27 Astrazeneca Ab Kombinationsterapi af ZD6474 med 5-FU og/eller CPT-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
NZ544458A (en) * 2003-07-10 2009-04-30 Astrazeneca Ab Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
EP1765313A2 (en) * 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
BRPI0516052A (pt) * 2004-09-27 2008-08-19 Astrazeneca Ab uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
DK1971338T3 (da) * 2005-12-22 2011-05-23 Astrazeneca Ab Kombination af ZD6474 og pemetrexed
WO2007139930A2 (en) * 2006-05-26 2007-12-06 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer
JP2010504949A (ja) * 2006-09-29 2010-02-18 アストラゼネカ アクチボラグ Ｚｄ６４７４とベバシズマブの癌療法のための組合せ
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
CA2723989C (en) * 2008-05-13 2017-04-25 Astrazeneca Ab Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
CN106478598B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
WO1997040835A1 (en) * 1996-04-26 1997-11-06 Magainin Pharmaceuticals Inc. Treatment of carcinomas using squalamine in combination with other anti-cancer agents
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
AU768027B2 (en) * 1999-02-24 2003-11-27 Uab Research Foundation, The Taxane derivatives for targeted therapy of cancer
JP4926320B2 (ja) * 1999-04-28 2012-05-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
CN100376567C (zh) * 1999-11-05 2008-03-26 阿斯特拉曾尼卡有限公司 作为vegf抑制剂的喹唑啉衍生物
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
BR0313116A (pt) * 2002-08-09 2005-07-05 Astrazeneca Ab Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como humano, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável.
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
DK1592423T3 (da) * 2003-02-13 2011-06-27 Astrazeneca Ab Kombinationsterapi af ZD6474 med 5-FU og/eller CPT-11
NZ544458A (en) * 2003-07-10 2009-04-30 Astrazeneca Ab Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
BRPI0516052A (pt) * 2004-09-27 2008-08-19 Astrazeneca Ab uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
DK1971338T3 (da) * 2005-12-22 2011-05-23 Astrazeneca Ab Kombination af ZD6474 og pemetrexed
JP2010504949A (ja) * 2006-09-29 2010-02-18 アストラゼネカ アクチボラグ Ｚｄ６４７４とベバシズマブの癌療法のための組合せ

Also Published As

Publication number Publication date
NZ532525A (en) 2006-11-30
DE60213845T2 (de) 2007-03-29
KR100959607B1 (ko) 2010-05-27
BR0213906A (pt) 2004-08-31
EP1446124B1 (en) 2006-08-09
US20050043395A1 (en) 2005-02-24
ZA200403455B (en) 2005-08-29
WO2003039551A1 (en) 2003-05-15
JP2005511597A (ja) 2005-04-28
JP4694127B2 (ja) 2011-06-08
AU2002337382B2 (en) 2008-06-12
DK1446124T3 (da) 2006-11-13
IL161744A (en) 2012-01-31
MXPA04004355A (es) 2004-08-11
GB0126879D0 (en) 2002-01-02
CN1298328C (zh) 2007-02-07
PT1446124E (pt) 2006-12-29
ES2269769T3 (es) 2007-04-01
KR20050043779A (ko) 2005-05-11
ATE335488T1 (de) 2006-09-15
NO20042365L (no) 2004-06-07
DE60213845D1 (de) 2006-09-21
NO328048B1 (no) 2009-11-16
IL161744A0 (en) 2005-11-20
AR037346A1 (es) 2004-11-03
CA2464758A1 (en) 2003-05-15
EP1446124A1 (en) 2004-08-18
US20120252827A1 (en) 2012-10-04
HK1068546A1 (en) 2005-04-29
CA2464758C (en) 2010-09-28
CN1612738A (zh) 2005-05-04

Similar Documents

Publication Publication Date Title
CY1106259T1 (el) Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο
CY1106601T1 (el) Χρηση του παραγωγου κουιναζολινης zd6474 συνδυασμενου με γκεμσιταμπινη και προαιρετικα με ιοντιζουσα ακτινοβολια στη θεραπεια του καρκινου
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
NO20064755L (no) Kombinasjonsterapi
NO20056171L (no) Kombinasjonsterapi
NO20064753L (no) Kombinasjonsterapi
NO20064754L (no) Kombinasjonsterapi
DE60308403D1 (de) Kombinationstherapie mit gemzitabin und zd6126